Sep 02 2022
HOKKAIDO LIFE SCIENCE SHOWCASE
JETRO Hokkaido, Hokkaido University, Sapporo City and CIC are hosting a cohort of life sciences startups from Hokkaido visiting Boston. Find out the cutting-edge life science technologies born out of Hokkaido, Japan and meet key players and researchers from Hokkaido community.
BOARD MEMBER, COO, GORYO CHEMICAL INC.
Potentials of our novel Navigation drug
Our Navigation Drug technology will cover any indication of diagnosis and surgical treatment by detecting the specific target biophysical materials. We seek global out-licensing or co-developing partners regarding Navigation Drugs or repositioning of potential partners’ ex-pipelines using Navigation Drugs.
FOUNDER, CTO, RAINBOW.INC
Specially designed stem cell for intra-cerebral transplantion
We have completed phase 1/2 clinical trials using proto-type stem cells and found excellent results (86% of patients regained ambulation). As we prepare for the next clinical trial in Japan, we seek collaboration with US partners for clinical trials in the US.
A highly-efficient, fully-autonomous drug screening platform
In our platform, we take genetically-engineered fruit flies (with homologs of 75% of disease-causing human genes) as patient models and unlock their full potential using advanced optics, microfluidics, and reinforcement learning. We expect this platform can dramatically reduce the cost, labor, and time for drug screenings.
ASSISTANT PROFESSOR,HOKKAIDO UNIVERSITY
Our original LNPs/ The reason of successful partnering with pharmaceutical companies
We have established a library of pH-responsive cationic lipids. Promising data and high potentials have drawn interest of many companies from Mega pharma to Biotech worldwide for the carrier of mRNA, siRNA and Cas9. We hope to expand partnering opportunity with companies in Boston for clinical applications of our LNPs.
PRESIDENT, LILAC PHARMA INC.
New microfluidic device for an effective mRNA vaccine production
Our novel microfluidic device enables timely global provision of effective mRNA vaccines without cold chain equipment. We have strength of developing microfluidic devices and we now seek partners (biotech company, academic institution, investor, etc.) who can realize the implementation our innovation.
CEO, AMS PLANNING, INC
Proposal from a nuclear medicine start-up
We are in-process of bringing a new prostate cancer diagnostic capability to the Japanese market in addition to working on the treatment side. AMS has built a talented team of medical, technical and business experts to progress pre-clinical R&D in preparation for Phase 1 clinical trial of 68Ga PSMA-11 PET in Recurrent Prostate Cancer scheduled in 1Q 2023. AMS seeks to raise $10M for Phase 2 and will execute bridging studies in the United States to omit Phase 3 clinical trial.